Previous Article | Next Article ![]()
University of Pittsburgh, Pittsburgh, PA; University of Florida College of Medicine, Gainesville, FL; MiraVista Diagnostics, Indianapolis, IN; Southern Arizona VA Health Care System-University of Arizona, Tucson AZ; Roudebush VA Medical Center-Indiana University School of Medicine, Indianapolis, IN; Bio-Rad Laboratories, Redmond, WA
We have evaluated the Platelia® Aspergillus enzyme immunoassay for detection of galactomannan in bronchoalveolar lavage (BAL) specimens in solid organ transplant patients with aspergillosis. Precision and reproducibility in serum or BAL to which galactomannan was added were similar. Sensitivity was 81.8% in patients with aspergillosis and specificity was 95.8% in lung transplant patients who underwent BAL for surveillance for infection or rejection. Among transplant controls, positive results were more common in patients who underwent diagnostic BAL performed for evaluation of symptoms or chest CT abnormalities, who had undergone lung transplantation, or were colonized with Aspergillus. Galactomannan testing in BAL is useful for diagnosis of aspergillosis in transplant patients. The significance of positive results in patients without confirmed aspergillosis requires further evaluation.
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Performance characteristics of the Platelia® Aspergillus EIA for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid
![]()
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»